DRUG
GLP-1 receptor agonist
Treatment with any GLP1 receptor agonist e.g. liraglutide, semaglutide, dulaglutide for either obesity or type 2 diabetes mellitus
Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health
Status
Unknown
Phase
Not applicable
Enrollment
20
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This study is investigating the effect of a medication called glucagon-like peptide 1 (GLP1) receptor agonists on mental health. GLP1 receptor agonists are a type of medication that are used to treat obesity and type 2 diabetes (T2D). Obesity and T2D are very common health conditions, and research has shown that people living with obesity and T2D are more likely to experience mental health disorders. Some recent research has suggested that GLP1 receptor agonists might help with mental health problems such as depression and binge eating disorder, and the investigators want to expand on this in this study. The investigators will be recruiting patients from community diabetes services, and tier 3 weight management services in South East London. Patients will be eligible if they are starting on GLP1 receptor agonists for the management of either T2D or obesity. The study is a mixed methods, longitudinal observations study with two components - a quantitative and a qualitative aspect. Firstly, the investigators will be interviewing patients before and 12-16 weeks after starting the medication, using short questionnaires which asks participants about different mental health symptoms that they may be experiencing. The investigators will use this information to see if there are any objective changes in mental health after taking GLP1 receptor agonists. Secondly, the investigators will be conducting a longer semi-structured interview after the second set of short questionnaires (at 12-16 weeks after starting GLP1 receptor agonist), asking about patient's experiences of taking the medication and how it has affected their mental health and general wellbeing. The investigators will qualitatively analyse this data to determine the subjective effect of GLP1 receptor agonists on mental health and wellbeing.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Aug 8, 2022
Study start
Sep 2022
Primary completion
Jun 2023
Study completion
Aug 2023
Results posted
Not reported
Registry updated
Sep 26, 2022
Outcomes
What the study measures.
Primary outcomes
subjective effect of GLP1 receptor agonist on mental health
Time frame · 12-16 weeks
qualitative analysis of the subjective effect of GLP1 receptor agonist on mental health in patients with diabetes and obesity (determined at stage 2 using the semi-structured interview)
Secondary outcomes
subjective effect of GLP1 receptor agonist on general wellbeing
Time frame · 12-16 weeks
qualitative analysis of the subjective effect of GLP1 receptor agonist on general wellbeing (determined at stage 2 using the semi-structured interview)
subjective effect of GLP1 receptor agonist on eating behaviours
Time frame · 12-16 weeks
qualitative analysis of the subjective effect of GLP1 receptor agonist on eating behaviours (determined at stage 2 using the semi-structured interview)
subjective effect of GLP1 receptor agonist on binge eating, if present
Time frame · 12-16 weeks
qualitative analysis of the subjective effect of GLP1 receptor agonist on binge eating, if present (determined at stage 2 using the semi-structured interview)
mean change in patient health questionnaire 9 (PHQ9) score with GLP1 receptor agonist over 12-16 weeks
Time frame · 12-16 weeks
mean change in PHQ9 score with GLP1 receptor agonist over 12-16 weeks (determined at stage 2 by comparing the questionnaire scores from stages 1 and 2). Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe.
mean change in generalised anxiety disorder assessment (GAD) score with GLP1 receptor agonist over 12-16 weeks
Time frame · 12-16 weeks
mean change in GAD score with GLP1 receptor agonist over 12-16 weeks (determined at stage 2 by comparing the questionnaire scores from stages 1 and 2). Score between 0 and 21; scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
mean change in eating disorder examination questionnaire (EDE-Q) score with GLP1 receptor agonist over 12-16 weeks
Time frame · 12-16 weeks
mean change in EDE-Q score with GLP1 receptor agonist over 12-16 weeks (determined at stage 2 by comparing the questionnaire scores from stages 1 and 2). Score between 0 and 168, higher scores on the global scale and subscales denote more problematic eating behaviours and attitudes
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * being commenced on a glucagon-like peptide 1 (GLP1) receptor agonist for management of either for obesity or type 2 diabetes * least 18 years of age * able to consent, speak and read in fluent English. Exclusion Criteria: * not able to consent, speak and read in fluent English
Study locations
1 registered sites.
United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Dulaglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly · Type 2 Diabetes
Phase 3
Recruiting
55
2026-07
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly · Diabetes Mellitus, Type 2
Phase 3
Not yet recruiting
170
2026-07
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
Brigham and Women's Hospital · Type 2 Diabetes
Not applicable
Completed
300,000
2026-07
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Brigham and Women's Hospital · Type 2 Diabetes · Overweight
Not applicable
Completed
60,000
2026-07
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
Brigham and Women's Hospital · Type 2 Diabetes Mellitus · Obesity
Not applicable
Completed
120,000
2026-07
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly · Type 2 Diabetes Mellitus
Phase 3
Completed
13,299
2026-07
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
ProGen. Co., Ltd. · Type 2 Diabetes
Phase 2
Not yet recruiting
60
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.